Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: Breakthrough HHV-6 encephalitis following antiviral prophylaxis

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 257-264

  Ogata, M ^a   Satou, T ^a   Inoue, Y ^a   Takano, K ^a   Ikebe, T ^a   Ando, T ^a   Ikewaki, J ^a   Kohno, K ^a   Nishida, A ^b   Saburi, M ^b   Miyazaki, Y ^b   Ohtsuka, E ^b   Saburi, Y ^b   Fukuda, T ^c   Kadota, J ^a  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b OITA PREFECTURAL HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

allo SCT; foscarnet; HHV 6 encephalitis; human herpesvirus 6; prophylaxis

Indexed keywords

FOSCARNET; VIRUS DNA;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DRUG INDUCED HEADACHE; FEMALE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; HUMAN HERPESVIRUS 6; INCIDENCE; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; TREND STUDY; VIRUS REACTIVATION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; ENCEPHALITIS, VIRAL; FOSCARNET; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 6, HUMAN; HUMANS; INCIDENCE; MIDDLE AGED; ROSEOLOVIRUS INFECTIONS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84873448294     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.121     Document Type: Article

References (28)

1. Yoshikawa T, Asano Y, Ihira M, Suzuki K, Ohashi M, Suga S et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: Clinical features and risk factors. J Infect Dis 2002; 185: 847-853
2. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40: 932-940
3. Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohno K et al. Human herpesvirus 6 DNA load in plasma after allogeneic stem cell transplantation: Incidence and clinical significance. J Infect Dis 2006; 193: 68-79
4. Yamane A, Mori T, Suzuki S, Mihara A, Yamazaki R, Aisa Y et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007; 13: 100-106
5. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18: 217-245
6. Ogata M. Human herpesvirus 6 in hematological malignancies. J Clin Exp Hematop 2009; 49: 57-67
7. Zerr DM. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol 2006; 37: 52-56
8. Muta T, Fukuda T, Harada M. Human herpesvirus-6 encephalitis in hematopoietic SCT recipients in Japan: A retrospective multicenter study. Bone Marrow Transplant 2008; 43: 583-585
9. Wainwright MS, Martin PL, Morse RP, Lacaze M, Provenzale JM, Coleman RE et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 2001; 50: 612-619
10. Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH et al. Posttransplant acute limbic encephalitis: Clinical features and relationship to HHV-6 Neurology 2007; 69: 156-165
11. Ogata M, Satou T, Kawano R, Goto K, Ikewaki J, Kohno K et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: A prospective evaluation. Bone Marrow Transplant 2008; 41: 279-285
12. Ogata M, Satou T, Kawano R, Takakura S, Goto K, Ikewaki J et al. Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2010; 45: 129-136
13. Fujimaki K, Mori T, Kida A, Tanaka M, Kawai N, Matsushima T et al. Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2006; 84: 432-437
14. Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 1596-1602
15. Sakai R, Kanamori H, Motohashi K, Yamamoto W, Matsuura S, Fujita A et al. Longterm outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1389-1394
16. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P et al. European Conference on Infections in Leukemia. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008; 42: 227-240
17. Ishiwata K, Kato D, Uchida N, Tsuji M, Yamamoto H, Araoka H et al. HHV-6- associated limbic encephalitis after umbilical cord blood transplantation. Jpn J Clin Hematol 2009; 50: 209 (Abstr. OS1-45) (in Japanese).
18. Ueki T, Satou K, Shimizu I, Akahane D, Ueno M, Ichikawa N et al. Five cases of post- CBT myelitis presenting with severe pain and clinical signs of dysautonomia. Jpn J Clin Hematol 2010; 51: 234 (Abstr. OS-1-108).
19. Numata A, Tanaka M, Tachibana T, Ozawa E, Ishigatsubo Y, Maruyama I et al. Risk factors for developing human herpes virus-6 encephalitis and clinical significance of antiviral therapy in early phase after allogeneic hematopoietic stem cell transplantation. Program Book for the 33rd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation 2011; P291 (Abstr. WS2-12-2) (in Japanese).
20. Zerr DM, Fann JR, Breiger D, Boeckh M, Adler AL, Xie H et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood 2011; 117: 5243-5249
21. Caserta MT, Dewhurst S. Dazed and confused by HHV-6. Blood 2011; 117: 5016-5018
22. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997; 90: 2502-2508
23. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD, Phase. I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473-479
24. Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788
25. Rapaport D, Engelhard D, Tagger G, Or R, Frenkel N. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002; 4: 10-16
26. Tokimasa S, Hara J, Osugi Y, Ohta H, Matsuda Y, Fujisaki H et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29: 595-598
27. Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V et al. Chromosomally integrated human herpesvirus 6: Questions and answers. Rev Med Virol 2012; 22: 144-155
28. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11: 381-395